XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Other Revenue (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue Recognition and Deferred Revenue [Abstract]  
Schedule of Disaggregation of Revenue
Net product sales by product were as follows (in millions):

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
COVID-19
$1,810 $1,757 $2,161 $3,878 
RSV
10 — 10 — 
Total $1,820 $1,757 $2,171 $3,878 
The following table summarizes product sales provision for the periods presented (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Gross product sales $2,964 $2,420 $3,377 $4,541 
Product sales provision:
Wholesaler chargebacks, discounts and fees
(1,053)(479)(1,053)(479)
Returns, rebates and other fees
(91)(184)(153)(184)
Total product sales provision(1)
$(1,144)$(663)$(1,206)$(663)
Net product sales $1,820 $1,757 $2,171 $3,878 
_______
(1)Includes an adjustment of approximately $140 million in the third quarter of 2024, reflecting a reduction in prior period provision estimates, primarily related to returns for the previous COVID-19 vaccine season that closed during the quarter.
The following table summarizes other revenue for the periods presented (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Grant revenue$7 $44 $27 $96 
Collaboration revenue28 30 35 63 
Licensing and royalty revenue
7 — 37 — 
Total other revenue$42 $74 $99 $159